| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/09/2013 | US20130116226 Method for treating esophageal cancer |
| 05/09/2013 | US20130116225 Method for treating hematological cancers |
| 05/09/2013 | US20130116224 Method and Composition for Treatment of Tumors |
| 05/09/2013 | US20130116223 Medicinal cosmetic lipoatrophy |
| 05/09/2013 | US20130116222 Dermal Delivery Compositions and Methods |
| 05/09/2013 | US20130116221 Theobromine for increasing hdl-cholesterol |
| 05/09/2013 | US20130116220 Polymeric Pheromone Formulation and Method of Use to Calm Stress-Related Behavior in Mammals over an Extended Period of Time |
| 05/09/2013 | US20130116219 Antimicrobial carboline compounds |
| 05/09/2013 | US20130116218 Methods and compositions of bile acids |
| 05/09/2013 | US20130116217 Neuroprotection and myelin repair using nestorone® |
| 05/09/2013 | US20130116216 Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| 05/09/2013 | US20130116215 Combination therapies for treating neurological disorders |
| 05/09/2013 | US20130116213 Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| 05/09/2013 | US20130116211 Novel Salts Of Boswellic Acids And Selectively Enriched Boswellic Acids And Processes For The Same |
| 05/09/2013 | US20130116209 Method for selection of chemotherapeutic agents for adenocarcinoma cancer |
| 05/09/2013 | US20130116208 Administration of a nedd8-activating enzyme inhibitor and hypomethylating agent |
| 05/09/2013 | US20130116207 Compositions and Methods for Treating Cancer |
| 05/09/2013 | US20130116206 Quinoline derivatives used as pet imaging agents |
| 05/09/2013 | US20130116205 Composition containing iridoids and uses thereof |
| 05/09/2013 | US20130116203 Isothiocynates and glucosinolate compounds and anti-tumor compositions containing same |
| 05/09/2013 | US20130116202 Ngna compositions and methods of use |
| 05/09/2013 | US20130116177 Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal |
| 05/09/2013 | US20130116174 Compositions and methods for increasing poultry hatchability and early performance |
| 05/09/2013 | US20130116169 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 05/09/2013 | US20130115696 siRNA that Inhibits WT1 Gene Expression and Uses Thereof |
| 05/09/2013 | US20130115589 Pharmaceutical Composition for Treatment and Prevention of Herpes Virus Infections |
| 05/09/2013 | US20130115316 Indolealkylamino-withasteroid conjugates and method of use |
| 05/09/2013 | US20130115314 Compounds Useful as Inhibitors of ATR Kinase |
| 05/09/2013 | US20130115313 Compounds Useful as Inhibitors of ATR Kinase |
| 05/09/2013 | US20130115312 Compounds Useful as Inhibitors of ATR Kinase |
| 05/09/2013 | US20130115311 Compounds Useful as Inhibitors of ATR Kinase |
| 05/09/2013 | US20130115310 Compounds Useful as Inhibitors of ATR Kinase |
| 05/09/2013 | US20130115309 Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells |
| 05/09/2013 | US20130115300 Ciprofloxacin dry syrup composition |
| 05/09/2013 | US20130115299 Method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells with microrna145 |
| 05/09/2013 | US20130115298 Extended release compositions comprising as active compound venlafaxine hydrochloride |
| 05/09/2013 | US20130115296 Methods for treating hepatocellular carcinoma |
| 05/09/2013 | US20130115290 Compositions for the symptomatic relief of stomach pain or gastrooesophageal reflux |
| 05/09/2013 | US20130115289 Anti-flush compositions |
| 05/09/2013 | US20130115288 Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
| 05/09/2013 | US20130115286 Oral administration forms for controlled release of rifampicin for the treatment of bacterial infections and inflammatory diseases of the gastrointestinal tract |
| 05/09/2013 | US20130115284 Omega3 fatty acid compound preparation |
| 05/09/2013 | US20130115283 Solid naproxen concentrates and related dosage forms |
| 05/09/2013 | US20130115280 Pharmaceutical and/or dietary compositions based on sort chain fatty acids |
| 05/09/2013 | US20130115274 Method of producing lipid nanoparticles for drug delivery |
| 05/09/2013 | US20130115273 Combinational Liposome Compositions for Cancer Therapy |
| 05/09/2013 | US20130115264 Implantable rasagiline compositions and methods of treatment thereof |
| 05/09/2013 | US20130115260 Antimicrobial composition |
| 05/09/2013 | US20130115257 Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates |
| 05/09/2013 | US20130115254 Aptamer-loaded, biocompatible nanoconstructs for nuclear-targeted cancer therapy |
| 05/09/2013 | US20130115247 Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy |
| 05/09/2013 | US20130115246 Reduced dose oral pharmaceutical compositions of fenofibrate |
| 05/09/2013 | US20130115228 Immunostimulatory combinations |
| 05/09/2013 | US20130115224 METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 05/09/2013 | US20130115222 Methods of limiting microvascular damage following acute myocardial ischemia |
| 05/09/2013 | US20130115221 HIFa prolyl hydroxylation assay |
| 05/09/2013 | US20130115214 Neuropilin antagonists |
| 05/09/2013 | US20130115202 Anti-inflammatory compositions for treating neuro-inflammation |
| 05/09/2013 | US20130115201 Fluid Supplement with Prenatal Vitamins |
| 05/09/2013 | US20130115200 Cell Therapy |
| 05/09/2013 | US20130115195 Anti-Aging Formulations |
| 05/09/2013 | US20130115194 Hepatitis c virus inhibitors |
| 05/09/2013 | US20130115193 Hepatitis C Virus Inhibitors |
| 05/09/2013 | US20130115186 Silicon-containing biodegradable material for anti-inflammatory therapy |
| 05/09/2013 | US20130115181 Aqueous pharmaceutical system for the administration of drugs to the nails |
| 05/09/2013 | US20130115180 Methods And Compositions For Administering A Specific Wavelength Phototherapy |
| 05/09/2013 | US20130115177 Topical compositions and methods for epithelial-related conditions |
| 05/09/2013 | US20130115174 Transmucosal composition containing anthocyanins for alleviating a visual discomfort |
| 05/09/2013 | US20130115133 Inactivation of microorganisms with multidrug resistance inhibitors and phenothiaziniums |
| 05/08/2013 | EP2589660A1 Compositions and methods for inhibiting expression of a gene from the Ebola |
| 05/08/2013 | EP2589603A1 Vegf production promoter |
| 05/08/2013 | EP2589601A1 Compound for inhibiting type 5 phosphodiesterase and preparation method thereof |
| 05/08/2013 | EP2589599A1 Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors |
| 05/08/2013 | EP2589597A2 Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR) |
| 05/08/2013 | EP2589595A1 Agent for treating hcv infection |
| 05/08/2013 | EP2589594A1 Ivabradine hydrochloride Form IV |
| 05/08/2013 | EP2589593A1 (2e)-3-phenyl-n-[2,2,2-trifluoro-1-[[(8-quinolineamino)thiomethyl]amino]ethyl]-2-acrylamide and pharmaceutical uses thereof |
| 05/08/2013 | EP2589592A1 Novel nicotinamide derivatives or salts thereof |
| 05/08/2013 | EP2589588A1 Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
| 05/08/2013 | EP2589388A1 Use of a Teichoic acid for the treatment of malignant ascites |
| 05/08/2013 | EP2589387A1 Use of a teichoic acid for the treatment of malignant liquor cerebrospinalis in the brain |
| 05/08/2013 | EP2589386A1 Method for inhibiting myopia and use of adenylate cyclase inhibitor as drug for inhibiting myopia |
| 05/08/2013 | EP2589385A1 Triple combination for the treatment of cancer |
| 05/08/2013 | EP2589384A1 New Pharmaceutical Compositions for the Treatment of Hyper-Proliferative Disorders |
| 05/08/2013 | EP2589383A1 FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
| 05/08/2013 | EP2589382A1 Pharmaceutical composition comprising levocarnitine and dobesilate |
| 05/08/2013 | EP2589381A1 Compositions for improving or preserving lung function in a patient with a pulmonary disorder |
| 05/08/2013 | EP2589379A2 Transdermal drug delivery system containing donepezil |
| 05/08/2013 | EP2589378A1 Coating of cetyl myristate and/or cetyl palmitate particles |
| 05/08/2013 | EP2589376A1 Oral disintegrating composition of anti-histamine agents |
| 05/08/2013 | EP2589302A1 Use of sphingomyelin and non-digestible carbohydrates for improving intestinal microbiota |
| 05/08/2013 | EP2589294A1 Compounds with nematicidal activity |
| 05/08/2013 | EP2589292A1 Compounds with nematicidal activity |
| 05/08/2013 | EP2588610A1 Calpain-3 inhibitors for treating muscular dystrophies and cardiomyopathies |
| 05/08/2013 | EP2588480A2 3,4-DIHYDROPYRROLO[1,2-A]PYRAZINE-2,8(1H)-DICARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF& xA; |
| 05/08/2013 | EP2588479A2 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors |
| 05/08/2013 | EP2588478A1 Azaindole derivative |
| 05/08/2013 | EP2588477A1 Quinolines as pi3k inhibitors |
| 05/08/2013 | EP2588476A1 Synthesis and use of kinase inhibitors |
| 05/08/2013 | EP2588475A1 Apoptosis signal-regulating kinase inhibitors |